Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
- PMID: 36575641
- PMCID: PMC9805988
- DOI: 10.1177/10600280221144932
Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Comment in
-
Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.Ann Pharmacother. 2023 Sep;57(9):1118-1119. doi: 10.1177/10600280221144936. Epub 2022 Dec 28. Ann Pharmacother. 2023. PMID: 36575975 Free PMC article. No abstract available.
Comment on
-
Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.Ann Pharmacother. 2023 Jul;57(7):769-775. doi: 10.1177/10600280221133376. Epub 2022 Oct 29. Ann Pharmacother. 2023. PMID: 36314277 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical